Safety and efficacy of CHOP for treatment of diffuse large B-cell lymphoma with different combination antiretroviral therapy regimens: SCULPT study

Antiviral Therapy

Volumn 18, Issue 5, 2013, Pages 699-707

  Wong, Alison Y J ^a   Marcotte, Suzanne ^b   Laroche, Mathieu ^b   Sheehan, Nancy L ^a,b   Kukreti, Vishal ^c   Routy, Jean Pierre ^a   Lemieux, Bernard ^b   Seki, Jack T ^c,d   Rouleau, Danielle ^b   Tseng, Alice ^c,d  

^a MCGILL UNIVERSITY HEALTH CENTRE   (Canada)

^b UNIVERSITÉ DE MONTRÉAL   (Canada)

^c UNIVERSITY HEALTH NETWORK   (Canada)

^d UNIVERSITY OF TORONTO   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

ATAZANAVIR PLUS RITONAVIR; CYCLOPHOSPHAMIDE; DIDANOSINE; DOXORUBICIN; EFAVIRENZ; GRANULOCYTE COLONY STIMULATING FACTOR; HUMAN IMMUNODEFICIENCY VIRUS PROTEINASE INHIBITOR; LOPINAVIR PLUS RITONAVIR; PREDNISONE; RALTEGRAVIR; RITONAVIR; RITUXIMAB; STAVUDINE; VINCRISTINE; ZIDOVUDINE;

ACUTE KIDNEY FAILURE; ADULT; ANEMIA; ARTICLE; BRAIN DISEASE; CANCER COMBINATION CHEMOTHERAPY; CANCER RECURRENCE; CANCER REGRESSION; CANCER SURVIVAL; CARDIOMYOPATHY; CD4 LYMPHOCYTE COUNT; CLINICAL ARTICLE; CONSTIPATION; CONTROLLED STUDY; CYSTITIS; DIARRHEA; DISEASE COURSE; DISEASE FREE SURVIVAL; DRUG DOSE REDUCTION; DRUG EFFICACY; DRUG SAFETY; FEBRILE NEUTROPENIA; FEMALE; HEMATURIA; HUMAN; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFECTION; INFUSION RELATED REACTION; INTERNATIONAL PROGNOSTIC INDEX; LARGE CELL LYMPHOMA; LUNG EMBOLISM; MALE; MIXED INFECTION; MYALGIA; NAUSEA; NEUROTOXICITY; OVERALL SURVIVAL; PILOT STUDY; PRIORITY JOURNAL; RETROSPECTIVE STUDY; SEIZURE; SIDE EFFECT; TRANSIENT ISCHEMIC ATTACK; TUMOR LYSIS SYNDROME; UNSPECIFIED SIDE EFFECT; VIRUS LOAD; VOMITING;

ADULT; ANTINEOPLASTIC AGENTS; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; ANTIRETROVIRAL THERAPY, HIGHLY ACTIVE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HIV INFECTIONS; HUMANS; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; NEOPLASM STAGING; PREDNISONE; RETROSPECTIVE STUDIES; TREATMENT OUTCOME; VINCRISTINE;

EID: 84888170510     PISSN: 13596535     EISSN: 20402058     Source Type: Journal    
DOI: 10.3851/IMP2572     Document Type: Article

References (30)

1. Shiels MS, Pfeiffer RM, Gail MH, et al. Cancer burden in the HIV-infected population in the United States. J Natl Cancer Inst 2011;103:753-762.
2. Franceschi S, Lise M, Clifford GM, et al. Changing patterns of cancer incidence in the early- and late-HAART periods: the Swiss HIV Cohort Study. Br J Cancer 2010;103:416-422.
3. Engels EA, Biggar RJ, Hall HI, et al. Cancer risk in people infected with human immunodeficiency virus in the United States. Int J Cancer 2008;123:187-194.
4. Lanoy E, Spano JP, Bonnet F, et al. The spectrum of malignancies in HIV-infected patients in 2006 in France: the ONCOVIH study. Int J Cancer 2011;129:467-475.
5. Ribera JM, Oriol A, Morgades M, et al. Safety and efficacy of cyclophosphamide, adriamycin, vincristine, prednisone and rituximab in patients with human immunodeficiency virus-associated diffuse large B-cell lymphoma: results of a phase II trial. Br J Haematol 2008;140:411-419.
6. Boué F, Gabarre J, Gisselbrecht C, et al. Phase II trial of CHOP plus rituximab in patients with HIV-associated non-Hodgkin's lymphoma. J Clin Oncol 2006;24:4123-4128.
7. Kaplan LD, Lee JY, Ambinder RF, et al. Rituximab does not improve clinical outcome in a randomized phase 3 trial of CHOP with or without rituximab in patients with HIV-associated non-Hodgkin lymphoma: AIDS-Malignancies Consortium Trial 010. Blood 2005;106:1538-1543.
8. Navarro WH, Kaplan LD. AIDS-related lymphoproliferative disease. Blood 2006;107:13-20.
9. Diamond C, Taylor TH, Im T, Anton-Culver H. Presentation and outcomes of systemic non-Hodgkin's lymphoma: a comparison between patients with acquired immunodeficiency syndrome (AIDS) treated with highly active antiretroviral therapy and patients without AIDS. Leuk Lymphoma 2006;47:1822-1829.
10. Navarro JT, Ribera JM, Oriol A, et al. Favorable impact of virological response to highly active antiretroviral therapy on survival in patients with AIDS-related lymphoma. Leuk Lymphoma 2002;43:1837-1842.
11. Weiss R, Mitrou P, Arasteh K, et al. Acquired immunodeficiency syndrome-related lymphoma: simultaneous treatment with combined cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy and highly active antiretroviral therapy is safe and improves survival-results of the German Multicenter Trial. Cancer 2006;106:1560-1568.
12. Navarro JT, Lloveras N, Ribera JM, et al. The prognosis of HIV-infected patients with diffuse large B-cell lymphoma treated with chemotherapy and highly active antiretroviral therapy is similar to that of HIV-negative patients receiving chemotherapy. Haematologica 2005;90:704-706.
13. Makinson A, Martelli N, Peyriere H, et al. Profound neutropenia resulting from interaction between antiretroviral therapy and vinblastine in a patient with HIV-associated Hodgkin's disease. Eur J Haematol 2007;78:358-360.
14. Vaccher E, Spina M, Di Gennaro G, et al. Concomitant cyclophosphamide, doxorubicin, vincristine, and prednisone chemotherapy plus highly active antiretroviral therapy in patients with human immunodeficiency virus-related, non-Hodgkin lymphoma. Cancer 2001;91:155-163.
15. Bower M, McCall-Peat N, Ryan N, et al. Protease inhibitors potentiate chemotherapy-induced neutropenia. Blood 2004;104:2943-2946.
16. Kotb R, Vincent I, Dulioust A, et al. Life-threatening interaction between antiretroviral therapy and vinblastine in HIV-associated multicentric Castleman's disease. Eur J Haematol 2006;76:269-271.
17. Ratner L, Lee J, Tang S, et al. Chemotherapy for human immunodeficiency virus-associated non-Hodgkin's lymphoma in combination with highly active antiretroviral therapy. J Clin Oncol 2001;19:2171-2178.
18. Antoniou T, Tseng AL. Interactions between antiretrovirals and antineoplastic drug therapy. Clin Pharmacokinet 2005;44:111-145.
19. Antoniou T, Tseng A. Potential interactions between antineoplastics and antiretrovirals. In Tseng A, Foisy M, editors. Handbook of HIV drug therapy. Toronto General Hospital: Toronto 2013; pp. 320-357.
20. Toffoli G, Corona G, Cattarossi G, et al. Effect of highly active antiretroviral therapy (HAART) on pharmacokinetics and pharmacodynamics of doxorubicin in patients with HIV-associated non-Hodgkin's lymphoma. Ann Oncol 2004;15:1805-1809.
21. Rescriptor (delavirdine mesylate). Product Monograph 2009. ViiV Healthcare ULC, Montreal, QC, Canada.
22. Mounier N, Katlama C, Costagliola D, Chichmanian RM, Spano JP. Drug interactions between antineoplastic and antiretroviral therapies: implications and management for clinical practice. Crit Rev Oncol Hematol 2009;72:10-20.
23. Levey AS, Coresh J, Greene T, et al. Expressing the modification of diet in renal disease study equation for estimating glomerular filtration rate with standardized serum creatinine values. Clin Chem 2007;53:766-772.
24. Cheson BD, Horning SJ, Coiffier B, et al. Report of an international workshop to standardize response criteria for non-Hodgkin's lymphomas. NCI Sponsored International Working Group. J Clin Oncol 1999;17:1244-1253.
25. Common Terminology Criteria for Adverse Events (CTCAE). US Department of Health and Human Services 2009 (Updated 14 June 2010. Accessed 19 November 2010.) Available from http://ctep.cancer.gov/protocolDevelopment/electronic- applications/ctc.htmtc-40
26. The International Non-Hodgkin's Lymphoma Prognostic Factors Project. A predictive model for aggressive non-Hodgkin's lymphoma. N Engl J Med 1993;329:987-994.
27. Castillo JJ, Echenique IA. Rituximab in combination with chemotherapy versus chemotherapy alone in HIV-associated non-Hodgkin lymphoma: a pooled analysis of 15 prospective studies. Am J Hematol 2012;87:330-333.
28. Wyen C, Jensen B, Hentrich M, et al. Treatment of AIDSrelated lymphomas: rituximab is beneficial even in severely immunosuppressed patients. AIDS 2012;26:457-464.
29. Haioun C, Salar A, Pettengell R, et al. Anemia and erythropoiesis- stimulating agent administration in patients with non-Hodgkin lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone ±rituximab chemotherapy: results from an observational study. Leuk Lymphoma 2011;52:796-803.
30. Vincrisitine sulfate injection. Product insert 2007. Hospira Healthcare Corporation, Lake Forest, IL, Australia.